Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,930.00
-20.00 (-0.34%)
Last updated: Oct 10, 2025, 2:00 PM KST
-0.34%
Market Cap77.03B
Revenue (ttm)n/a
Net Income (ttm)-10.53B
Shares Out12.95M
EPS (ttm)-813.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,499
Average Volume50,147
Open6,000.00
Previous Close5,950.00
Day's Range5,770.00 - 6,000.00
52-Week Range5,300.00 - 11,960.00
Beta0.33
RSI52.45
Earnings DateNov 14, 2025

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.